Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study

Mohammed Tarek Alam, Rubaiul Murshed, Pauline Francisca Gomes, Zafor Md. Masud, Sadia Saber, Mainul Alam Chaklader, Fatema Khanam, Monower Hossain, Abdul Basit Ibne Momen Momen, Naz Yasmin, Rafa Faaria Alam, Amrin Sultana and Rishad Choudhury Robin
Additional contact information
Mohammed Tarek Alam: Bangladesh Medical College Hospital, Bangladesh
Rubaiul Murshed: Shomman Foundation, Bangladesh
Pauline Francisca Gomes: Shomman Foundation, Bangladesh
Zafor Md. Masud: Bangladesh Medical College Hospital, Bangladesh
Sadia Saber: Bangladesh Medical College Hospital, Bangladesh
Mainul Alam Chaklader: Bangladesh Medical College Hospital, Bangladesh
Fatema Khanam: Bangladesh Medical College Hospital, Bangladesh
Monower Hossain: Bangladesh Medical College Hospital, Bangladesh
Abdul Basit Ibne Momen Momen: Bangladesh Medical College Hospital, Bangladesh
Naz Yasmin: International Medical College, Bangladesh
Rafa Faaria Alam: Bangladesh Medical College Hospital, Bangladesh
Amrin Sultana: Bangladesh Medical College Hospital, Bangladesh
Rishad Choudhury Robin: Shomman Foundation, Bangladesh

European Journal of Medical and Health Sciences, 2020, vol. 2, issue 6

Abstract: Introduction: While multiple vaccines are undergoing clinical trial across the globe, we yearn for an FDA approved drug to protect us from the devastating pandemic for the time being. This study aims to determine the effectiveness of Ivermectin when administered as pre-exposure prophylaxis for COVID-19. Method: An observational study, with 118 healthcare providers who were enrolled purposively, was conducted in a tertiary hospital in Dhaka from May 2020 to August 2020. The subjects were divided into experimental and control groups; and the experimental group received an oral monthly dose of Ivermectin 12mg for 4 months. Both groups were exposed to COVID-19 positive patients admitted in the hospital during the course of study. The symptomatic subjects were evaluated by physical examination, COVID-19 RT-PCR and/or HRCT of chest. Differences between the variables were determined using the Chi-square test and the level of statistical significance was reached when p

Keywords: COVID-19; Ivermectin; Prophylaxis; Healthcare worker; Bangladesh (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://eu-opensci.org/index.php/ejmed/article/view/40599 Abstract page (text/html)
https://eu-opensci.org/index.php/ejmed/article/download/40599/9067 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:epw:ejmed0:v:2:y:2020:i:6:id:40599

DOI: 10.24018/ejmed.2020.2.6.599

Access Statistics for this article

More articles in European Journal of Medical and Health Sciences from European Open Science
Bibliographic data for series maintained by Support ().